Practical Approach to Treating Growth Hormone Deficiency: How to Leverage Registries to Guide Treatment Decisions - Episode 4
Leveraging Growth Hormone Registries to Inform Long-Term Treatment Decisions
An expert discusses how clinicians can apply registry data alongside randomized trial evidence to address long-term safety, persistence, and real-world outcomes in growth hormone therapy.
In this segment, Joshua Yang, MD, offers a practical perspective on how clinicians should incorporate registry data into decision-making for patients receiving growth hormone therapy, including long-acting formulations. He emphasizes that registries should be viewed as a complement, rather than a replacement, for randomized clinical trials.
Randomized trials remain the gold standard for demonstrating efficacy under controlled conditions, but their relatively short duration and selective inclusion criteria limit the ability to fully characterize rare safety events, long-term outcomes, and treatment patterns in heterogeneous populations.
Yang highlights treatment persistence as a central domain where registries provide critical insights beyond those available from trials. In randomized studies, adherence is typically high and closely monitored, whereas registry data reflect the realities of day-to-day use in the community. With long-acting GH analogs, registries can help determine whether reduced injection frequency translates into improved persistence and, ultimately, better growth outcomes such as height velocity and near-adult height.
Additionally, he notes that registries allow clinicians to answer questions that families frequently pose, such as what to expect at 5, 10, or 15 years of therapy and how outcomes compare among patients with similar diagnoses or baseline characteristics.
Looking ahead, Yang anticipates that growth hormone registries will become even more informative as they integrate electronic health records, adherence metrics, and patient-reported outcomes. This evolution will expand their role from primarily safety surveillance to a more comprehensive characterization of real-world effectiveness, quality of life, and care patterns.
By synthesizing data from randomized trials and registries, clinicians will be better equipped to counsel families about long-term expectations, balance benefits and risks, and individualize therapy across the spectrum of GHD and related indications. Yang suggests that this trajectory mirrors the historical experience with daily GH and will be essential for building similar confidence in long-acting analogs over the coming decades.
